Your Custom Text Here
Experts argue preventative screening should become new standard of care
In an editorial in the journal Frontiers in Neurology, two leading multiple sclerosis (MS) experts are advocating for genetic testing to identify MS patients who are at higher risk of developing a devastating side effect from their medications.
Read moreResults published in Frontiers in Neurology may lead to an 11% reduction in PML caused by immune-modifying medications
New research has confirmed a strong link between four genetic mutations and progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection that can be triggered by dozens of FDA-approved drugs.
Read morePopulation Bio (PB) – a global leader in gene discovery announced, in support of World Rare Disease Day, its continued investment in its CNV Beacon® gene discovery platform which delivers new knowledge about rare diseases.
Read morePopulation Diagnostics – a global leader in gene discovery for complex disease announced today that it is changing its corporate name to Population Bio.
Read moreCollaboration Announced Between Researchers at University of California Irvine and Population Diagnostics,
Inc. at Rare Disease Event in Southern California
The Parkinson's Institute and Clinical Center announced today that they, in partnership with Population Diagnostics, Inc., have discovered a number of new genes relevant to the cause of Parkinson's disease.
The innovative approach used for this study focuses first on genome-wide investigation of gene copy number variants (CNVs) followed by targeted sequencing of CNV-identified candidate genes.
Read morePeer-Reviewed Findings Provide Medically Relevant Content for Early Detection Pre-symptomatic Diagnostics for Autism as well as New Insights into Drug Discovery
Study Demonstrates Potential of Population Diagnostics' Gene Discovery Platform
Read morePress Release – Melville, NY – September 15, 2011 – Population Diagnostics, Inc. (PDx), a private company with a novel approach for systematically uncovering the genetic causes of disease as well as the genetic basis of drug efficacy and safety, announced today the appointment of Sir Walter Bodmer to its Scientific Advisory Board.
Read morePress Release –Melville, NY– May 17, 2010 – Population Diagnostics, Inc. (PDx), a private company with a novel approach to revealing the genetic causes of disease and predicting drug response, announced today it has been awarded a federal grant to identify the genetic causes of Parkinson’s Disease. Funded by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health, the project is being led by Eli Hatchwell, MD, PhD, an Associate Professor at Stony Brook University Medical Center and a co-founder of PDx.
Read morePress Release – Melville, NY – January 13, 2010 – Population Diagnostics, Inc. (PDx), a private company developing a new generation of molecular diagnostic and personalized medicine companion tests, announced today the appointment of Dr. Peggy Eis as Chief Technology Officer
Read morePress Release – Melville, NY – June 17, 2008 – Population Diagnostics, Inc. (PDx) announced today that it has won a technology innovation awarded by NY Loves Bio… sponsoring PDx in the New York Pavilion at the BIO 2008 International Conference
Read more